Therapeutic effect of Xialiqi Capsule on benign prostatic hyperplasia
- Conditions
- benign prostatic hyperplasia
- Registration Number
- ITMCTR2100005234
- Lead Sponsor
- Second Hospital of Tianjin Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- Not specified
1. Patients with BPH who have symptoms of frequent urination and dysuria, diagnosed by digital rectal examination, B-ultrasound, and uroflowmetry.
2. IPSS>=13 and/or QOL>=3 points.
3. Prostate volume > 25ml.
4. The maximum urine flow rate is less than 15ml/s.
5. Residual urine volume <100ml.
6. Aged > 50 years.
7. The patients voluntarily participated and signed the informed consent.
8. PSA<4ng/ml or PSA>4ng/ml, but exclude patients with prostate cancer.
9. In line with the dialectical standard of TCM spleen-kidney qi deficiency and phlegm stasis syndrome.
1. With other diseases that cause urination disorders, such as prostate cancer.
2. The patient or his authorizer is unwilling to comply with the study protocol.
3. Upper urinary tract hydrops, bladder stones, repeated hematuria, urinary tract infections caused by benign prostatic hyperplasia.
4. Patients with benign prostatic hyperplasia who have failed invasive treatment and who have a history of pelvic surgery or injury.
5. Patients with severe diabetes, hypertension, cardiovascular and cerebrovascular diseases.
6. Patients with major organ dysfunction, such as liver and kidney insufficiency.
7. Psychopaths.
8. Those with allergies.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method